Vilanterol: A Key Component in COPD and Asthma Management

A long-acting beta-adrenoceptor agonist used in combination with other medications to treat chronic obstructive pulmonary disease (COPD) and asthma.

Vilanterol FAQ

Image credit: salcobrand.cl

Is vilanterol a carcinogen?

In a 2-year carcinogenicity study in rats, vilanterol caused statistically significant increases in mesovarian leiomyomas in females and a shortening of the latency of pituitary tumors at inhaled doses greater than or equal to 84.4 mcg/kg/day (greater than or equal to approximately 20 times the MRHDID for adults on an AUC basis).

How does vilanterol work?

Vilanterol is a long-acting beta-2 agonist. It works by attaching to beta-2 receptors found in the muscle cells of many organs. When inhaled, vilanterol reaches the receptors in the airways and activates them. This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.

What is the pharmacological effect of vilanterol?

Vilanterol is a selective long-acting beta2-adrenergic agonist. Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP).

Is vilanterol a bronchodilator?

Inhaled vilanterol is a long-acting bronchodilator. Bronchodilators are medicines that are breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. This medicine is available only with your doctor's prescription. Copyright: © Merative US L.P. 1973, 2024.

Is vilanterol a long-acting adrenoreceptor agonist?

Vilanterol ( INN, USAN) is an ultra-long-acting β 2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). .

Is vilanterol a long-acting beta-2 agonist?

Vilanterol is a long-acting beta-2 agonist available only in a combination inhaler with fluticasone furoate or/and with umeclidinium. Which short-acting beta-2 agonists are available for COPD, and what dose should I prescribe? Aerosol inhalation — 100 micrograms to 200 micrograms (1–2 puffs) up to four times daily.